Adjuvant chemotherapy versus observation following neoadjuvant therapy and surgery for resectable stage I-II pancreatic cancer.
Sung Jun MaLucas M SerraAustin J BartlHye Ri HanFatemeh FekrmandiAustin J IovoliGregory M HermannHan YuAnurag K SinghPublished in: Journal of radiotherapy in practice (2021)
Using propensity score matched analysis, our findings suggest a survival benefit for adjuvant chemotherapy compared to observation following NT and surgery for resectable pancreatic adenocarcinoma, especially in patients with smaller tumors. Prospective studies are needed to identify subset of patients that would benefit from adjuvant chemotherapy.
Keyphrases
- minimally invasive
- locally advanced
- end stage renal disease
- coronary artery bypass
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- surgical site infection
- liver metastases
- lymph node
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- stem cells
- bone marrow
- cell therapy
- smoking cessation
- free survival